These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 31783597

  • 1. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Oh JH, Jang YS, Kang D, Chang DK, Min YW.
    Nutrients; 2019 Nov 27; 11(12):. PubMed ID: 31783597
    [Abstract] [Full Text] [Related]

  • 2. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 27; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 3. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 27; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 4. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial.
    Sadrin S, Sennoune SR, Gout B, Marque S, Moreau J, Grillasca J, Pons O, Maixent JM.
    Cell Mol Biol (Noisy-le-grand); 2017 Sep 30; 63(9):122-131. PubMed ID: 28980935
    [Abstract] [Full Text] [Related]

  • 5. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial.
    Bauserman M, Michail S.
    J Pediatr; 2005 Aug 30; 147(2):197-201. PubMed ID: 16126049
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
    Didari T, Mozaffari S, Nikfar S, Abdollahi M.
    World J Gastroenterol; 2015 Mar 14; 21(10):3072-84. PubMed ID: 25780308
    [Abstract] [Full Text] [Related]

  • 7. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V, Gschossmann J, Layer P.
    Lancet Gastroenterol Hepatol; 2020 Jul 14; 5(7):658-666. PubMed ID: 32277872
    [Abstract] [Full Text] [Related]

  • 8. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives.
    Maixent JM, Pons O, Sennoune SR, Sadrin S.
    Cell Mol Biol (Noisy-le-grand); 2020 Jun 05; 66(3):211-214. PubMed ID: 32538776
    [Abstract] [Full Text] [Related]

  • 9. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B.
    Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763
    [Abstract] [Full Text] [Related]

  • 10. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial.
    Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, Zinoune K, Grillasca JP, Pons O, Maixent JM.
    Dig Liver Dis; 2020 May 26; 52(5):534-540. PubMed ID: 31952938
    [Abstract] [Full Text] [Related]

  • 11. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
    Martoni CJ, Srivastava S, Leyer GJ.
    Nutrients; 2020 Jan 30; 12(2):. PubMed ID: 32019158
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H.
    Neurogastroenterol Motil; 2015 May 30; 27(5):705-16. PubMed ID: 25809913
    [Abstract] [Full Text] [Related]

  • 13. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.
    Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):387-94. PubMed ID: 16128676
    [Abstract] [Full Text] [Related]

  • 14. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A.
    J Clin Gastroenterol; 2017 Jan 01; 51(1):e5-e10. PubMed ID: 27306945
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.
    Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE.
    Scand J Gastroenterol; 2013 Oct 01; 48(10):1127-35. PubMed ID: 23957590
    [Abstract] [Full Text] [Related]

  • 16. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S, Mora D, Gschwender M, Popp K.
    Aliment Pharmacol Ther; 2011 May 01; 33(10):1123-32. PubMed ID: 21418261
    [Abstract] [Full Text] [Related]

  • 17. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J.
    World J Gastroenterol; 2014 Jul 14; 20(26):8709-16. PubMed ID: 25024629
    [Abstract] [Full Text] [Related]

  • 18. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 19. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ.
    Sci Rep; 2018 Feb 14; 8(1):2964. PubMed ID: 29445178
    [Abstract] [Full Text] [Related]

  • 20. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
    Sisson G, Ayis S, Sherwood RA, Bjarnason I.
    Aliment Pharmacol Ther; 2014 Jul 14; 40(1):51-62. PubMed ID: 24815298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.